WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
WX [WuXi PharmaTech (Cayman)] 6-K: Form 6-K TABLE OF CONTENTS Page 3 4
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
SVA [SINOVAC BIOTECH] SC 13D/A: (Original Filing)
[13D CUSIP No. P8696W104 Page 2 1. Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above Persons John M. Gregory 2. Check the Appropriate Box if a Member of a Group (See Instructions) ¨ x (a) 3. SEC Use Only 4. Source of Funds (See Instructions) OO 5. 6. Citizenship or Place of Organization]
SVA [SINOVAC BIOTECH] SC 13D/A: 13D CUSIP No. P8696W104 Page 2 1. Names
[13D CUSIP No. P8696W104 Page 2 1. Names of Reporting Persons. S.S. or I.R.S. Identification Nos. of Above Persons John M. Gregory 2. Check the Appropriate Box if a Member of a Group (See Instructions) ¨ x (a) 3. SEC Use Only 4. Source of Funds (See Instructions) OO 5. 6. Citizenship or Place of Organization]
TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)
[TPI Reports Second Quarter Fiscal Year 2014 Financial Results CHENGDU, China, February 14, 2014 -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter of fiscal year 2014. Second Quarter Fiscal 2014 Ended December 31,] [Tianyin Pharmaceutical Inc. Second Quarter Fiscal Year 2014 Financial Results Conference Call February 14, 2014 Operator I will now turn the presentation over to James Tong, CFO of the Company. Dr. Tong: Second Quarter of Fiscal 2014 Ended December 31, 2013 Financial Highlights: ● Revenue was $13.9 million versus $17.6 million in the second quarter FY 2013, a decrease of] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K Current Report February 14, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction Identification No.) (IRS Employer of incorporation) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
TPI [TIANYIN PHARMACEUTICAL] 8-K: TPI Reports Second Quarter Fiscal Year 2014 Financial
[TPI Reports Second Quarter Fiscal Year 2014 Financial Results CHENGDU, China, February 14, 2014 -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter of fiscal year 2014. Second Quarter Fiscal 2014 Ended December 31,] [Tianyin Pharmaceutical Inc. Second Quarter Fiscal Year 2014 Financial Results Conference Call February 14, 2014 Operator I will now turn the presentation over to James Tong, CFO of the Company. Dr. Tong: Second Quarter of Fiscal 2014 Ended December 31, 2013 Financial Highlights: ● Revenue was $13.9 million versus $17.6 million in the second quarter FY 2013, a decrease of] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K Current Report February 14, 2014 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction Identification No.) (IRS Employer of incorporation) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)
[Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating Results as Compared With Last Year’s USD$21.8 million loss from operations XIANYANG, China, February 20, 2014 –Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 20, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
BSPM [Biostar Pharmaceuticals] 8-K: Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth
[Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating Results as Compared With Last Year’s USD$21.8 million loss from operations XIANYANG, China, February 20, 2014 –Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 20, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]
TPI [TIANYIN PHARMACEUTICAL] SC 13G: for a reporting persons initial filing on this
[for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose (Act) or otherwise subject to]
SVA [SINOVAC BIOTECH] SC 13G: (Original Filing)
[(Name of Issuer) Common Stock (Title of Class of Securities) P8696W104 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. P8696W104 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY]
